Wow (and a double Wow!).

ACTISAVE Trial

Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of Stroke
zpr.io/nQsYJBXCJUTG
#PharmTech #Pharma ceuticalNews #Analysis #Data #Investment #DrugDiscovery #COVID19 #Regulation #Mergers #WhosWho #Pharma #healthtec

🔬 Acticor Biotech présentera les résultats cliniques de son étude de phase 2/3 ACTISAVE dans le traitement de l’AVC à l’ESOC 2024 du 15 au 17 mai

➡️ newcontact.eu/secure/media/c…

$ALACT #acticor #biotech #AVC

Exciting news: More Large Clinical Trials to be presented at #ESOC2024 :
- ANNEXA-I
- TACTICS
- REMOTE-CAT
- RICH-2
- RECLAIM II
- CLEVER
- ACTISAVE
- INTERACT
- ANNEXA-I
- EMBOLISE
- SELECT2
- TENSION
- MR CLEAN No-IV
- TWIN2WIN

👉 ow.ly/50l750RqSpR

#stroke #stroke twitter

ตัววิตามินลดสิวเค้าจะทำงาน 3 ขั้นตอน
🏷ลดการอุดตันและลดความมันบนใบหน้า ด้วยสารสกัด ACTISAVE ลดความมัน
🏷ลบเลือนรอยสิว ด้วย L-Cycsteine Glycine L-Glutamine
🏷ป้องกันการเกิดสิวใหม่ เสริมผิวให้แข็งแรงจากสารสกัดธรรมชาติ Horsetails,Grape Seed,Pine Bark, Collagen,Vitamin C

#CommuniquéDePresse 🗞️

Acticor Biotech a finalisé le recrutement des patients de son étude de phase 2/3 ACTISAVE dans l’AVC

Plus d'infos 👉 newcontact.eu/secure/media/c…

$ALACT #biotech #AVC

Acticor Biotech présentera les résultats cliniques de son étude de phase 2/3 ACTISAVE dans le traitement de l’AVC à l’ESOC 2024 dlvr.it/T5XWSL

ACTICOR adapte son étude clinique ACTISAVE en vue de l’enregistrement du glenzocimab pour le traitement de l’AVC dlvr.it/Sw5sYJ

#ESOC2022 updates: Pr Mikael Mazighi just presented promising results from Actimis trial on glenzocimab in the acute phase of ischemic stroke - Large Clinical Trial session European Stroke Org Hôpital Lariboisière - Fernand-Widal AP-HP Acticor Biotech - stay tuned, ACTISAVE study is ongoing!

ACTICOR BIOTECH : Résultats principaux de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVC dlvr.it/T5zbkj

PRESS RELEASE 📃

Acticor Biotech announces the enrollment of the first US patient in its phase 2/3 study ACTISAVE for the treatment of stroke ! 🇺🇸🧠

👉 More informations : uploads-ssl.webflow.com/60ed4d6a6fc45c…

#pressrelease #US #ACTISAVE #glenzocimab #biotech #stroke #healthcare

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment dlvr.it/T5zbJh

ACTIMIS preliminary results suggest glenzocimab in addition to reperfusion therapies reduce symptomatic ICH events and death. Will need confirmation from large studies ACTISAVE and GREEN
#esoc2022 European Stroke Org

🔄 Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 #ACTISAVE study in stroke !🧠

👩‍🔬 438 patients with stroke have been randomized

🗓 Clinical results for the second quarter 2024

👉 Read the full press release here : lnkd.in/eGKAAwgA

Dive into cutting-edge stroke science at this year's #ESOC2024 ! We're thrilled to present some major clinical trials that are set to make waves: ow.ly/6U9850RcSMJ

🔹CHARM
🔹ACTISAVE

🔹INTERACT4
🔹SWITCH
#strokeresearch #voiceofstroke Urs Martin Fischer #stroketwitter

Acticor modifies ACTISAVE study for glenzocimab's stroke treatment registration preparation.

More Info: pryzm.ozmosi.com/product/20973 $XBI $IBB $XPH $PPH

Acticor Biotech reçoit l'approbation de l'Agence européenne des médicaments (EMA) sur les paramètres clés d'ACTISAVE, son étude pivot de phase 2/3 pour le traitement de l'AVC dlvr.it/SdtH5y

ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatment of Stroke dlvr.it/Sw5sTS

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment cardiacvascularnews.com/acticor-biotec…

Acticor Biotech first 🇺🇸 US ACTISAVE Investigators’ Meeting happening in NOLA! This impressive group of Acute Ischemic Stroke experts is as optimistic as we are about the potential for glenzocimab to change the AIS treatment paradigm🧠

acticor-biotech.com